Step-by-step guides, research summaries, and treatment overviews β reviewed by oncology navigators and written clearly for patients, families, and caregivers.
From newly diagnosed to relapsed and refractory β we publish what patients actually need to understand their options.
What are you looking for today?
CancerFax Insights exists because cancer patients face decisions that are genuinely hard β not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.
Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?
Use the search and filters below to find what's most relevant to your situation.
Step-by-step patient guide
Before agreeing to CAR-T therapy, families need to understand eligibility criteria, the manufacturing timeline, expected side effects, and what happens if the therapy fails. This guide walks through every question your team should be able to answer.
Browse by the topic most relevant to where you are in your cancer journey right now.
Compare options, evaluate trade-offs, understand what questions to ask before agreeing to a specific protocol.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening.
NGS testing, biomarker-based treatment matching, liquid biopsy, tumour mutation burden, and targeted therapy guides.
Cross-border treatment pathways, China and India access, visa planning, cost estimates, and logistics walk-throughs.
Practical guides for families, partners, and adult children walking alongside someone in cancer treatment.
How to prepare records, frame clinical questions, compare opinions, and navigate specialist review across borders.
Search, filter, and explore all published insights β by cancer type, treatment category, clinical trial readiness, or stage of your journey.
Search across cancer types, treatments, mutations, drugs, and trials
CAR-T
CAR-T therapy in China costs $100,000β180,000 all-in for the full treatment episode, compared to $500,000β700,000 in the USA and comparable figures in Europe. Approved Chinese CAR-T products including relma-cel and BCMA-targeted therapies offer equivalent efficacy at a fraction of Western drug prices. CancerFax navigates cost, hospital selection, and access logistics for international patients.
CAR-T India
B-cell aplasia is an expected on-target effect of CD19 CAR-T therapy, lasting a median of 6β12 months with NexCAR19. In India, IVIG replacement is available at Rs 5,000β15,000 per infusion β approximately $60β180 β far cheaper than Western pricing. Outpatient IVIG infusion is accessible across Apollo, Kokilaben, Manipal, and Max networks, allowing patients to return home after discharge from the CAR-T centre.
CAR-T
India and China are the two most accessible countries globally for CAR-T therapy. India offers the world's lowest-cost approved CD19 CAR-T (NexCAR19 at $30β40K) with easier visa and English communication. China offers the broadest target range β BCMA, GPRC5D, CLDN18.2, dual-target β and the most clinical trial options for myeloma and solid tumours. The right choice depends on your disease, target, and geography.
CAR-T Autoimmune
Anti-CD19 CAR-T therapy has shown remarkable results in autoimmune conditions including SLE, myasthenia gravis, anti-synthetase syndrome, and systemic sclerosis β primarily through the work of Professor Georg Schett's group in Erlangen, Germany. Before starting, patients should ask 11 key questions covering eligibility, targets, risks, comparison to standard immunosuppression, and access pathways.
CAR-T India
CancerFax provides end-to-end coordination for international patients seeking NexCAR19 or Kymriah CAR-T therapy in India β from eligibility pre-screening and hospital selection to e-medical visa support, interpreter coordination, and post-discharge monitoring. The typical timeline from first contact to CAR-T infusion is 55β70 days.
CAR-T Cell Therapy
Relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) is one of the most compelling indications for CAR-T therapy β with complete remission rates of 70β90% even in chemotherapy-resistant disease. China's haematology centres, led by PKUPH and Ruijin Hospital, offer CD19-directed CAR-T for paediatric and adult B-ALL with outcomes consistent with global pivotal trials and at substantially lower cost.
CAR-T
ICANS (immune effector cell-associated neurotoxicity syndrome) is the second most common serious toxicity after CAR-T therapy, presenting as confusion, aphasia, tremor, or seizure. It is graded using CARTOX-10 or ASTCT scoring and treated with dexamethasone; grade 3β4 cases require ICU-level care.
CAR-T
Allogeneic (off-the-shelf) CAR-T therapy uses donor-derived T-cells manufactured in advance, eliminating the 3β6 week wait of autologous manufacturing. Chinese programmes from CAStem Therapeutics and Gracell/AstraZeneca are among the most advanced globally, currently in Phase IβII trials.
CAR-T
Solid tumours remain the frontier challenge for CAR-T therapy due to the immunosuppressive tumour microenvironment, antigen heterogeneity, and poor T-cell trafficking. China is running the world's largest portfolio of solid tumour CAR-T trials targeting CLDN18.2 (gastric/pancreatic), GPC3 (liver cancer), GD2 (neuroblastoma), and mesothelin (lung, ovarian, mesothelioma).
Where are you in your cancer journey? Find insights matched to your current situation.
Understand your diagnosis, staging, reports, and first-line options before making major decisions.
Read newly-diagnosed insightsExplore second opinions, molecular testing, clinical trials, and international advanced options.
Explore next-step insightsLearn how trial matching, eligibility review, and mutation-based screening actually work.
View clinical trial insightsUnderstand how destination, treatment availability, cost, and expertise shape cross-border decisions.
Compare destinationsCurated reading lists for patients going deep into a specific treatment category or clinical question.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
Explore insights and guides organised by the treatment modality most relevant to your case.
Find content specific to your diagnosis β from treatment overviews to clinical trial access and second opinion guidance.
Clinical trial access
CancerFax connects patients with clinical trials in China, India, and leading global centres β including phase I and II trials closed to international enrolment through standard channels.
500+
active clinical trials across China, India, and leading global centres
40+
cancer types with current advanced therapy access pathways
12+
years of patient navigation experience in cross-border oncology
Insights our navigation team recommends most often to patients starting their research.
Treatment guide Β· 8 min
02Second opinion Β· 6 min
03Precision oncology Β· 10 min
04Clinical trials Β· 7 min
05Clinical trials Β· 9 min
06Precision oncology Β· 5 min
A note from the CancerFax team
CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear β not what any institution wants them to read.
That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes β even when the honest answer is harder to hear.
β CancerFax oncology navigation team
How our content is produced, reviewed, and how to use it effectively.
Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres β wherever you are in the world.
Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.
